VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
for
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer,
Location: 14 recruiting locations
Sponsor: VM Oncology, LLC
Sex: All
Age: 18 - 70+
Code: NCT03556228
Phase1, Phase2, Recruiting
Active & Responsive
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
for
Esophageal Squamous Cell Carcinoma
Location: 4 recruiting locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT05319730
Phase1, Phase2, Recruiting
Active & ResponsiveNew
IKS014 in Advanced Solid Tumors That Express HER2
for
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Location: 3 recruiting locations
Sponsor: Iksuda Therapeutics Ltd.
Sex: All
Age: 18+
Code: NCT05872295
Phase1, Recruiting
Active & ResponsiveNew
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
for
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer,
Location: 2 recruiting locations
Sponsor: Radiopharm Theranostics, Ltd
Sex: All
Age: 18+
Code: NCT07189871
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
for
Barrett Esophagus, Gastroesophageal Reflux,
Location: 3 recruiting locations
Sponsor: Case Comprehensive Cancer Center
Sex: All
Age: 50+
Code: NCT06687603
Recruiting
Active & Responsive
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
for
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Location: 1 recruiting location
Sponsor: University of Wisconsin, Madison
Sex: All
Age: 18+
Code: NCT04150640
Phase2, Recruiting
Active & Responsive
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)